Brain-Controlled Spinal Stimulation for Spinal Cord Injury
Trial Summary
What is the purpose of this trial?
The purpose of this research is to test the effectiveness of a new therapy, called Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS), for improving walking in people with an incomplete spinal cord injury (SCI).
Do I need to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications, but it excludes individuals on investigational drugs or any intervention that could affect neuromotor function.
What data supports the effectiveness of the treatment BCI-TSCS for spinal cord injury?
Research shows that transcutaneous spinal cord stimulation (tSCS), a component of BCI-TSCS, can help improve motor function in people with spinal cord injuries by stimulating the spinal cord non-invasively. Studies have found that tSCS can enhance sensorimotor recovery and facilitate motor responses, suggesting its potential effectiveness in rehabilitation.12345
Is Brain-Controlled Spinal Stimulation generally safe for humans?
Transcutaneous spinal cord stimulation (tSCS), a component of the treatment, is non-invasive and has been studied in people with spinal cord injuries, showing it can stimulate spinal circuits without major safety concerns. However, more specific safety data for the combined use with brain-computer interfaces is limited.16789
How is the treatment BCI-TSCS different from other treatments for spinal cord injury?
BCI-TSCS is unique because it combines brain-computer interface technology with transcutaneous spinal cord stimulation, allowing for non-invasive stimulation of the spinal cord to enhance motor function. This approach is novel as it potentially enables the brain to directly influence spinal cord activity, which is different from traditional methods that do not integrate brain signals.1231011
Research Team
Matija Milosevic, PhD
Principal Investigator
University of Miami - MSOM
Eligibility Criteria
This trial is for adults aged 21-70 with an incomplete spinal cord injury at or above T10 level, who are more than 6 months post-injury. Participants must have some detectable motor function in their legs and be able to walk at least 10 meters with assistance. They should commit to a 6-month training program and not have metal implants affected by magnetic stimulation, severe spasticity, skin breakdown where electrodes attach, recent seizures, major cognitive issues, or substance disorders.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS) therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BCI-TSCS
BCI-TSCS is already approved in United States, Switzerland for the following indications:
- Improving walking in individuals with incomplete spinal cord injury (SCI)
- Rehabilitation of walking in individuals with incomplete spinal cord injury (SCI)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Miami
Lead Sponsor
United States Department of Defense
Collaborator